KEY TAKEAWAYS
- The study aimed to investigate the link between MMP-2 promoter polymorphisms and BC risk.
- Results showed that MMP-2 rs243865 and rs2285053 genotypes appear to have minimal impact on individual susceptibility to BC or TNBC.
Matrix metalloproteinase-2 (MMP-2) plays a role in the development of breast cancer (BC). However, research on the relationship between MMP-2 genotypes and BC risk is limited.
Chih-Chiang Hung and the team aimed to investigate the associations between the 2 MMP-2 promoter polymorphisms, rs243865 and rs2285053, and BC risk.
Researchers selected a cohort of 1,232 BC cases and 1,232 controls. PCR-based RFLP methodology was used to analyze MMP-2 genotypes.
Results showed that genotypic frequencies of MMP-2 rs243865 and rs2285053 in controls were consistent with Hardy-Weinberg equilibrium (P=0.3702 and 0.2036, respectively). No significant differences were found in the distribution of rs243865 and rs2285053 genotypes between BC cases and controls (P for trend=0.1602 and 0.2170, respectively).
Although variant genotypes at rs243865 and rs2285053 appeared to confer a protective effect, it was not statistically significant (all P>0.05). Similarly, the variant T allele at rs243865 and rs2285053 showed a non-significant trend toward decreased BC risk (OR=0.84 and 0.89, 95%CI=0.69-1.02 and 0.78-1.02, P=0.0811 and 0.1043, respectively).
No interaction was observed between MMP-2 rs243865 or rs2285053 genotypes and age. The stratified analysis revealed no significant associations between MMP-2 rs243865 or rs2285053 genotypes and triple-negative breast cancer (TNBC) (P=0.6458 and 0.8745, respectively). Among both TNBC and non-TNBC cases, none of the variant genotypes at rs243865 or rs2285053 showed significant associations with TNBC (all P>0.05).
The study concluded that MMP-2 rs243865 and rs2285053 genotypes have minimal impact on individual susceptibility to breast cancer or triple-negative breast cancer.
No funding information was available.
Source: https://pubmed.ncbi.nlm.nih.gov/39191502/
Hung CC, Tsai CL, Chin YT, et al. (2024). “Impacts of Matrix Metalloproteinase-2 Promoter Genotypes on Breast Cancer Risk.” Cancer Genomics Proteomics. 2024;21(5):502-510. doi:10.21873/cgp.20467
